View Item 

Show simple item record

The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â institution study from the US Neuroendocrine Tumor Study Group
dc.contributor.authorZaidi, Mohammad Y.
dc.contributor.authorLopez‐aguiar, Alexandra G.
dc.contributor.authorPoultsides, George A.
dc.contributor.authorDillhoff, Mary
dc.contributor.authorRocha, Flavio G.
dc.contributor.authorIdrees, Kamran
dc.contributor.authorNathan, Hari
dc.contributor.authorWinslow, Emily R.
dc.contributor.authorFields, Ryan C.
dc.contributor.authorCardona, Kenneth
dc.contributor.authorMaithel, Shishir K.
dc.date.accessioned2019-01-15T20:31:09Z
dc.date.available2020-03-03T21:29:35Zen
dc.date.issued2019-01
dc.identifier.citationZaidi, Mohammad Y.; Lopez‐aguiar, Alexandra G. ; Poultsides, George A.; Dillhoff, Mary; Rocha, Flavio G.; Idrees, Kamran; Nathan, Hari; Winslow, Emily R.; Fields, Ryan C.; Cardona, Kenneth; Maithel, Shishir K. (2019). "The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â institution study from the US Neuroendocrine Tumor Study Group." Journal of Surgical Oncology 119(1): 5-11.
dc.identifier.issn0022-4790
dc.identifier.issn1096-9098
dc.identifier.urihttps://hdl.handle.net/2027.42/147162
dc.publisherSpringer
dc.publisherWiley Periodicals, Inc.
dc.subject.otherinsulinoma
dc.subject.otherrecurrence
dc.subject.othersymptomatic
dc.subject.otherVIPoma
dc.subject.othergastrinoma
dc.subject.otherglucagonoma
dc.titleThe impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8â institution study from the US Neuroendocrine Tumor Study Group
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelSurgery and Anesthesiology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147162/1/jso25306_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147162/2/jso25306.pdf
dc.identifier.doi10.1002/jso.25306
dc.identifier.sourceJournal of Surgical Oncology
dc.identifier.citedreferenceMadeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998; 43 ( 3 ): 422 â 427.
dc.identifier.citedreferenceDickson PV, Behrman SW. Management of pancreatic neuroendocrine tumors. Surg Clin North Am. 2013; 93 ( 3 ): 675 â 691.
dc.identifier.citedreferenceParbhu SK, Adler DG. Pancreatic neuroendocrine tumors: contemporary diagnosis and management. Hosp Pract (1995). 2016; 44 ( 3 ): 109 â 119.
dc.identifier.citedreferenceAnderson CW, Bennett JJ. Clinical presentation and diagnosis of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am. 2016; 25 ( 2 ): 363 â 374.
dc.identifier.citedreferenceCougard P, Goudet P, Peix JL, et al. Insulinomas in multiple endocrine neoplasia type 1. Report of a series of 44 cases by the multiple endocrine neoplasia study group. Ann Chir. 2000; 125 ( 2 ): 118 â 123.
dc.identifier.citedreferenceJensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008; 113 ( 7 Suppl ): 1807 â 1843.
dc.identifier.citedreferenceMarx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129 ( 6 ): 484 â 494.
dc.identifier.citedreferenceNorton JA, Cornelius MJ, Doppman JL, Maton PN, Gardner JD, Jensen RT. Effect of parathyroidectomy in patients with hyperparathyroidism, Zollingerâ Ellison syndrome, and multiple endocrine neoplasia type I: a prospective study. Surgery. 1987; 102 ( 6 ): 958 â 966.
dc.identifier.citedreferenceO’Riordain DS, O’Brien T, van Heerden JA, Service FJ, Grant CS. Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg. 1994; 18 ( 4 ): 488 â 493. Discussion 93â 4.
dc.identifier.citedreferenceRoy PK, Venzon DJ, Shojamanesh H, et al. Zollingerâ Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000; 79 ( 6 ): 379 â 411.
dc.identifier.citedreferenceThakker RV. Multiple endocrine neoplasia type 1. Endocrinol Metab Clin North Am. 2000; 29 ( 3 ): 541 â 567.
dc.identifier.citedreferenceZerbi A, Capitanio V, Boninsegna L, et al. Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. Langenbecks Arch Surg. 2011; 396 ( 3 ): 313 â 321.
dc.identifier.citedreferenceCrippa S, Zerbi A, Boninsegna L, et al. Surgical management of insulinomas: shortâ and longâ term outcomes after enucleations and pancreatic resections. Arch Surg. 2012; 147 ( 3 ): 261 â 266.
dc.identifier.citedreferenceWatzka FM, Laumen C, Fottner C, et al. Resection strategies for neuroendocrine pancreatic neoplasms. Langenbecks Arch Surg. 2013; 398 ( 3 ): 431 â 440.
dc.identifier.citedreferenceNorton JA. Endocrine tumours of the gastrointestinal tract. Surgical treatment of neuroendocrine metastases. Best Pract Res Clin Gastroenterol. 2005; 19 ( 4 ): 577 â 583.
dc.identifier.citedreferenceSarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003; 12 ( 1 ): 231 â 242.
dc.identifier.citedreferenceSutcliffe R, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. Am J Surg. 2004; 187 ( 1 ): 39 â 46.
dc.identifier.citedreferenceNeuroendocrine Tumors. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, III, AT, eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010:pp. 181 â 185.
dc.identifier.citedreferenceChi W, Warner RRP, Chan DL, et al. Longâ term outcomes of gastroenteropancreatic neuroendocrine tumors. Pancreas. 2018; 47 ( 3 ): 321 â 325.
dc.identifier.citedreferenceModlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant. Langenbecks Arch Surg. 2011; 396 ( 8 ): 1145 â 1156.
dc.identifier.citedreferencePhan GQ, Yeo CJ, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg. 1998; 2 ( 5 ): 472 â 482.
dc.identifier.citedreferenceNorton JA, Sugarbaker PH, Doppman JL, et al. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg. 1986; 203 ( 4 ): 352 â 359.
dc.identifier.citedreferenceBartsch DK, Langer P, Wild A, et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance? Surgery. 2000; 128 ( 6 ): 958 â 966.
dc.identifier.citedreferenceNorton JA, Fang TD, Jensen RT. Surgery for gastrinoma and insulinoma in multiple endocrine neoplasia type 1. J Natl Compr Canc Netw. 2006; 4 ( 2 ): 148 â 153.
dc.identifier.citedreferenceLi J, Yang Y, Zhou X, et al. Micrometastasis expressing insulin arise in lung and spleen at advanced stage of rip1â tag2 transgenic mice. Int J Biol Sci. 2014; 10 ( 2 ): 136 â 141.
dc.identifier.citedreferenceAuernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S et al. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. Lancet Diabetes Endocrinol. 2018; 6 ( 5 ): 404 â 415.
dc.identifier.citedreferenceDimitriadis GK, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016; 23 ( 9 ): R423 â R436.
dc.identifier.citedreferenceOberg K, Jelic S, Group EGW. Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendations for diagnosis, treatment and followâ up. Ann Oncol. 2008; 19 ( Suppl 2 ): ii104 â ii105.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
jso25306_am.pdf
Size:
189.8KB
Format:
PDF
View/Open
Name:
jso25306.pdf
Size:
506.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.